STOCK TITAN

Renalytix Plc - RNLX STOCK NEWS

Welcome to our dedicated news page for Renalytix Plc (Ticker: RNLX), a resource for investors and traders seeking the latest updates and insights on Renalytix Plc.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Renalytix Plc's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Renalytix Plc's position in the market.

Rhea-AI Summary
Renalytix plc (RNLX) announces the inclusion of KidneyIntelX in the 2024 KDIGO Clinical Practice Guideline for CKD management. The guideline emphasizes risk prediction for disease progression and personalized treatment. Renalytix received FDA de-novo marketing authorization for KidneyIntelX in June 2023, with positive outcomes data supporting its use.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.19%
Tags
none
-
Rhea-AI Summary
Renalytix plc reported financial results for the fiscal second quarter ended December 31, 2023, showcasing revenue growth, reimbursement coverage, and cost management improvements. KidneyIntelX saw increased sales and FDA approval, with real-world evidence supporting its efficacy. Operating cost reductions were significant, leading to a reduced cash burn rate. Despite a decrease in revenue compared to the previous year, the company has taken steps to lower expenses and preserve revenue generating activities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.12%
Tags
earnings
-
Rhea-AI Summary
Renalytix plc (RNLX) to participate in BTIG MedTech Conference in Snowbird, Utah without a formal presentation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-29.57%
Tags
conferences
Rhea-AI Summary
Renalytix plc (RNLX) announces positive real-world evidence for KidneyIntelX in slowing chronic kidney disease progression and improving Type 2 diabetes control. The study, including 2,569 patients with Type 2 diabetes and diabetic kidney disease, showed a 61% increase in preventative drug prescriptions among high-risk patients and improved specialist referrals, leading to reduced cost of care and improved patient outcomes. The FDA has issued a de Novo Marketing Authorization for the KidneyIntelX.dkd version of the test, with an addressable market of approximately 14 million patients with adult diabetes and kidney disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.89%
Tags
none
-
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) reported financial results for fiscal Q1 ended September 30, 2023. Recent highlights include ongoing financing discussions, cost-cutting initiatives, FDA authorization of kidneyintelX.dkd, Medicare reimbursement process advancements, senior executive appointment, and distribution agreement execution. The company also revealed first quarter 2024 financial results, with a $0.5 million revenue and a net loss of $10.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-37.5%
Tags
earnings
-
Rhea-AI Summary
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) will report its Q1 fiscal year 2024 financial results on November 14, 2023, before market open. A conference call and webcast to discuss the results, business strategy, partnerships, and regulatory processes will follow at 8:30 a.m. (ET) / 1:30 p.m. (GMT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.92%
Tags
conferences earnings
Rhea-AI Summary
Renalytix receives new notice of allowance for patent claims related to kidneyintelX.dkd test
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.52%
Tags
none
-
Rhea-AI Summary
Renalytix reports financial results for fiscal year 2023, achieving FDA authorization for KidneyIntelX.dkd and securing additional insurance coverage contracts. Maintaining contracted pricing at $950 per test result. Executed over 40 commercial payor contracts and enrolled in 35 state Medicaid programs. Reduction in test volumes at Mount Sinai during commercial insurance billing transition. Appointed Howard Doran as senior diagnostics executive. Full Epic EHR integration with Atrium/Wake Forest underway. Agreement with Veterans Affairs. Milestone achievement in insurance payment availability. Multiple clinical and validation studies presented. KidneyIntelX associated with improved patient outcomes and increased SGLT2-inhibitor drug therapy usage. Completed $20.3 million equity financing. Reduced annual operating expenses by over $11 million. Over 5,000 KidneyIntelX tests performed in FY 2023. Expanded board of directors. Conference call scheduled to discuss financial results and key topics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.96%
Tags
earnings
-
Rhea-AI Summary
Renalytix plc to report Q4 and full year fiscal 2023 financial results on September 28, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.96%
Tags
conferences earnings
Rhea-AI Summary
Renalytix appoints Howard Doran as Chief Business Officer to lead KidneyIntelX global sales effort.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.32%
Tags
management
Renalytix Plc

Nasdaq:RNLX

RNLX Rankings

RNLX Stock Data

51.56M
71.45M
4.66%
8.64%
1.49%
Diagnostic Imaging Centers
Health Care and Social Assistance
Link
United Kingdom
Penarth

About RNLX

renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev